The Seventh Circuit Court of Appeals has reinstated a lawsuit filed by Teva Pharmaceuticals USA, Inc. against Eli Lilly and Company. The court's decision, issued on July 13, 2026, allows Teva to pursue its claim that Lilly violated a settlement agreement related to the drug Forteo. This ruling is significant for the pharmaceutical industry as it addresses the complexities of patent settlements and the obligations of brand-name drug manufacturers.
Teva Pharmaceuticals, a generic drug manufacturer, is affected by this ruling as it seeks to enter the market with a generic version of Forteo, a medication used to treat osteoporosis. The outcome of this case could impact the competitive landscape for generic drugs and the enforcement of settlement agreements in the pharmaceutical sector.
Background
The dispute between Teva and Eli Lilly began with a previous lawsuit in 2016, when Lilly accused Teva of infringing several patents related to Forteo. Teva had filed an Abbreviated New Drug Application (ANDA) with the FDA for a generic version of the drug, which led to the patent infringement claim. Under the Hatch-Waxman Act, generic manufacturers like Teva can challenge brand-name patents, risking litigation but potentially gaining market exclusivity if successful.
In January 2018, Teva and Lilly reached a settlement agreement that allowed Teva to enter the market with a generic version of Forteo by August 12, 2019, while Lilly agreed not to obstruct Teva’s approval process. However, after the Forteo patents expired on August 19, 2019, Teva alleges that Lilly took actions that delayed its entry into the market, including filing a supplemental New Drug Application that extended Lilly’s market exclusivity.
The Ruling
The Seventh Circuit, led by Judge Hamilton, reversed the district court's dismissal of Teva's breach of contract claim. The court found that Teva had plausibly alleged that Lilly breached terms of the settlement agreement that were still in effect even after the expiration of the Forteo patents. The court stated, "The generic manufacturer has plausibly alleged breaches of contract terms that were still in effect. Its complaint and briefing did not need to specify the agreement’s termination date more precisely."
The ruling emphasized that the settlement agreement did not explicitly state when it would expire, and under Indiana law, contracts can remain in effect for a reasonable time even if no end date is specified. The court concluded that it was reasonable to interpret the settlement agreement as still binding, particularly regarding Lilly's obligation not to interfere with Teva's ability to launch its generic drug.
Impact
This ruling has significant implications for both Teva and the broader pharmaceutical industry. It underscores the importance of clarity in settlement agreements and the obligations that may persist even after patent expiration. The decision allows Teva to pursue its claims against Lilly, which could lead to financial compensation or a resolution that enables Teva to enter the market sooner.
The case also sets a precedent for how courts may interpret the duration of contractual obligations in the context of pharmaceutical settlements. It highlights the need for brand-name manufacturers to adhere to their commitments, even after the underlying patents have expired, potentially influencing future negotiations and agreements in the industry.
What's Next
The case will now return to the lower court for further proceedings. Teva's breach of contract claim will be evaluated in detail, and both parties may present additional evidence and arguments. It remains to be seen whether Lilly will appeal the Seventh Circuit's decision or if there are any related cases pending.